Shots: The US FDA has granted FTD to losmapimod for the treatment of FSHD while the therapy has previously received ODD for FSHD The company will present full data from […]readmore
Tags : Losmapimod
COVID-19
Pharma
Fulcrum Initiates P-III LOSVID Study Evaluating Losmapimod for Patients Hospitalized
Shots: The P-III LOSVID study assess the safety and efficacy of losmapimod (15mg, bid) vs PBO for 14 days on top of SOC in ~400 patients hospitalized with COVID-19 and […]readmore
Shots: GSK to receive shares of Fulcrum’s preferred stock, milestones & royalties on sales of losmapimod. Fulcrum to get exclusive WW rights to develop & commercialize of losmapimod with all […]readmore